An Evaluation of the Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET (Stress-Rest) Myocardial Perfusion Imaging (MYPERS)

There is limited information on what causes injury to the heart in individuals with Sickle Cell Disease (SCD). Researchers in this study want to see if decreased blood flow to the heart during stress could be causing the heart damage seen in SCD patients. They also want to test people who don't have SCD to see if their hearts react the same way under stress.
Primary Objective
* To estimate the coronary flow reserve (CFR) (also referred to as myocardial perfusion reserve), as measured by PET stress-rest myocardial perfusion imaging, in SCD patients with and without diastolic dysfunction, and healthy controls.
Secondary Objectives
* To investigate the relationship between decreased CFR (quantified with PET stress- rest myocardial perfusion imaging) and presence of abnormal diastolic parameters

Start Date10 Oct 2023

Sponsor / Collaborator

St. Jude Children's Research Hospital, Inc.

NCT05625490

/ RecruitingEarly Phase 1IIT

Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging

A single center, phase 0/1 clinical imaging study designed to assess the role of [68Ga]Galmydar PET/CT imaging in human subjects.

Start Date11 Nov 2022

Sponsor / Collaborator

Washington University School of Medicine

[+2]

NCT04870827

/ TerminatedNot ApplicableIIT

The Effect of Chronic Inflammation on Myocardial Perfusion and Function

Background:
Heart failure (HF) is a public health burden. Studies have shown a link between inflammation, myocardial dysfunction, and HF. Researchers want to use psoriasis as a disease model of chronic inflammation to further study the link between inflammation and myocardial dysfunction.
Objective:
To learn if chronic inflammation affects the heart and if taking a biological medicine for chronic inflammation helps improve how the heart works.
Eligibility:
Adults ages 18 and older who have moderate to severe psoriasis, and healthy adult volunteers.
Design:
Participants will be screened with a medical history. They may take a pregnancy test.
Healthy volunteers will have 1 visit. Those with psoriasis will have a second visit 1 year later.
Participants may give blood samples. They may have a heart function test. They may have a heart imaging test, and may get a contrast agent. If so, it will be injected into a vein.
Participants may have positron emission tomography/computed tomography tests. They will lie on their back on a padded table with their arms straight overhead. They may get radioactive drugs through an intravenous (IV) catheter. They will get stress medicines through the IV. These drugs mimic exercise and increase blood flow through the heart.
Participants may have cardiac magnetic resonance imaging. The scanner is a large tube. Participants will lie on a table that slides in and out of the tube. They will get gadolinium contrast in a vein to improve the pictures. They may get stress medicines. Coils will be used to help make the pictures.
Participation for healthy volunteers will last 1-2 days. Participation for those with psoriasis will last 14 months.
...

Start Date07 Jun 2021

Sponsor / Collaborator

National Heart, Lung & Blood Institute

100 Clinical Results associated with AMMONIA N-13

100 Translational Medicine associated with AMMONIA N-13

100 Patents (Medical) associated with AMMONIA N-13

238

Literatures (Medical) associated with AMMONIA N-13

01 Nov 2024·Journal of Computational Biophysics and Chemistry

Molecular Docking, Quantum Mechanics and Molecular Dynamics Simulation of Anti-CAD Drugs Against High-Risk Xanthine Dehydrogenase Variants Associated with Oxidative Stress Pathways

Author: Ahmed, Shiek S. S. J. ; Sudhan, M. ; Emran, Talha Bin ; Attia, Sabry M. ; Ahmad, Sheikh F. ; Janakiraman, V.

Xanthine dehydrogenase (XDH) contributes significantly to generating reactive oxygen species in coronary artery disease (CAD). XDH has been proposed as a therapeutic target, but its genetic variants could affect protein structure and drug response. We aimed to assess protein structure modification occur due to genetic variants and to screen 215 CAD drugs for their utility in personalized CAD treatment against the XDH variants. A series of computational methods were implemented to identify pathogenic variants that cause XDH structure instability localized at the con served regions contributing to functional significance. Then, the XDH structures with the pathogenic variants were modeled using two different approaches to select the best models for docking with the CAD drugs. Finally, the stability of the docked complexes and their ability to transfer electrons were evaluated using molecular dynamics (MD) simulations and quantum mechanics/molecular mechanics (QM/MM) calculation. Among 751 variants examined; R149C and Q919R showed high pathogenicity, localized in conserved regions could alter protein structure and function. Further, docking of CAD drugs against XDH (native, R149C and Q919R) showed vericiguat with higher affinity, ranging from −7.95 kcal/mol to −10.41 kcal/mol, than the well-known XDH inhibitor (febuxostat, −5.73 kcal/mol to −8.35 kcal/mol). This indicates that vericiguat will be effective in CAD treatment, regardless of the XDH variants. Additionally, MD simulation and QM/MM confirmed vericiguat stability and electron transfer ability to form hydrogen bonds with the XDH protein. In conclusion, vericiguat will be beneficial for the personalized treatment of CAD by inhibiting XDH variants. Additional clinical studies are necessary to confirm our findings.

01 Sep 2023·Medical physics

Improved accuracy of the biodistribution and internal radiation dosimetry of ¹³N‐ammonia using a total‐body PET/CT scanner

Article

Author: Han, Yuan ; Huang, Gang ; Wang, Cheng ; Yu, Xiaofeng ; Xu, Lian ; Liu, Jianjun ; Qiu, Ju ; Shi, Fuxiao ; Sun, Hongyan ; Li, Lianghua ; Zhou, Yun ; Ng, Yee Ling ; Chen, Yumei

Abstract:

Background:

Conventional short‐axis PET typically utilizes multi‐bed multi‐pass acquisition to produce quantitative whole‐body dynamic images and cannot record all the uptake information simultaneously, resulting in errors when fitting the time‐activity curves (TACs) and calculating radiation doses.

Purpose:

The aim of this study is to evaluate the 13N‐ammonia biodistribution and the internal radiation doses using a 194 cm long total‐body PET/CT scanner (uEXPLORER), and make a comparison with the previous short‐axis PET results.

Methods:

Ten subjects (age 40–74 years) received 13N‐NH3 injection (418.1‐670.81 MBq) and were under a dynamic scan for about 60 min with using a 3‐dimensional whole‐body protocol. ROIs were drawn visually on 11 major organs (brain, thyroid, gallbladder, heart wall, kidneys, liver, pancreas, spleen, lungs, bone marrow, and urinary bladder content) for each subject. TACs were generated using Pmod and the absorbed radiation doses were calculated using Olinda 2.2. To compare with the conventional PET/CT, five points were sampled on uEXPLORER's TACs to mimic the result of a short‐axis PET/CT (15 cm axial FOV, consisted of 9 or 10 bed positions). Then the TACs were obtained using the multi‐exponential fitting method, and the residence time and radiation dose were also calculated and compared with uEXPLORER.

Results:

The highest absorbed organ doses were the pancreas, thyroid, spleen, heart wall, and kidneys for the male. For the female, the first five highest absorbed organ dose coefficients were the pancreas, heart wall, spleen, lungs, and kidneys. The lowest absorbed dose was found in red marrow both for male and female. The simulated short‐axis PET can fit TACs well for the gradually‐changed uptake organs but typically underestimated for the rapid‐uptake organs during the first‐10 min, resulting in errors in the calculated radiation dose.

Conclusion:

uEXPLORER PET/CT can measure 13N‐ammonia's TACs simultaneously in all organs of the whole body, which can provide more accurate biodistribution and radiation dose estimation compared with the conventional short‐axis scanners.

25 Apr 2023·Journal of Nippon Medical School = Nippon Ika Daigaku zasshi

Estimation of Microvascular Dysfunction by Using <sup>13</sup>N-Ammonia Positron Emission Tomography with Quantitative Myocardial Blood Flow Analysis in Chronic Coronary Syndrome

Article

Author: Kumita, Shin-ichiro ; Kiriyama, Tomonari ; Imai, Shogo ; Aoyama, Satoe ; Kanaya, Koji ; Takano, Hitoshi

BACKGROUND:

Although coronary artery disease (CAD) is characterized by epicardial atherosclerosis and microvascular disease, the importance of evaluating microvascular dysfunction has not been sufficiently recognized in clinical practice. We estimated microvascular disease severity by assessing hyperemic microvascular resistance (MVR), as determined by absolute quantification of myocardial blood flow (MBF) with ¹³N-ammonia positron emission tomography-myocardial perfusion imaging (PET-MPI).

METHODS:

We retrospectively collected data for 23 CAD patients who underwent both stress/rest PET-MPI and invasive coronary angiography (CAG) with fractional flow reserve (FFR) measurement. Among 30 vessels for which FFR measurement was performed, 13 had a low FFR (FFR ≤0.75). For each patient, myocardial segments of a standard 17-segment model were assigned to the stenotic myocardial area perfused by the FFR-measured vessel and a reference normal-perfusion area based on PET-MPI and the coronary distribution on CAG. Hyperemic MVR was calculated by using the formula, hyperemic MVR = hyperemic mean blood pressure × FFR/hyperemic MBF of the stenotic vessel.

RESULTS:

A strong negative correlation was observed between hyperemic MVR and hyperemic MBF in the reference normal-perfusion area (R = -0.758, P<0.001).

CONCLUSION:

Microvascular disease severity in chronic CAD can be estimated by hyperemic MBF of the normal-perfusion area with ¹³N-ammonia PET-MPI.

News (Medical) associated with AMMONIA N-13

15 Nov 2023

·www.prnewswire.com

Ionetix to provide Bayer with Therapeutic Radioisotope Actinium-225 (Ac-225)

LANSING, Mich., Nov. 15, 2023 /PRNewswire/ -- Ionetix Corporation today announced the signing of a supply agreement for the therapeutic radioisotope actinium-225 (Ac-225) with Bayer. Under the terms of the agreement, Ionetix will provide Bayer with high-purity, non-carrier added (n.c.a.) Ac-225. Ac-225 is an alpha-emitter and when attached to a tumor seeking molecule, can deliver therapeutic doses of radiation directly to tumors, destroying the cancer cells while sparing the surrounding healthy tissue. Precision targeting of cancer using targeted radionuclide therapies (TRT) is a promising new cancer treatment approach. However, the global availability of Ac-225 is limited and currently there are very few production resources. Therefore, there is an immediate need for new sources of Ac-225 supply that can scale effectively to support the development of these new cancer treatments. "We recognized the emerging demand and made the early investment to develop a commercial-scale production solution for Ac-225 using our expertise in cyclotron accelerator and target technology," said David Eve, VP of Medical Affairs for Ionetix Corporation. Located in Lansing, Michigan, Ionetix has established a new isotope production facility that is dedicated to manufacturing alpha-emitters. The first cyclotron was commissioned at the facility earlier this year and installation of a second cyclotron is planned for 2024. Both cyclotrons will be used to produce alpha-emitters, providing both onsite redundancy and increased capacity to scale output. Distribution of GMP grade, n.c.a. Ac-225 will begin in early 2024. About IONETIX Utilizing a proprietary cyclotron technology platform, Ionetix is focused on developing innovative solutions for the production and distribution of radioisotopes used for diagnostic and therapeutic radiopharmaceuticals. Ionetix offers turnkey services for the point-of-care supply of diagnostic positron emission tomography (PET) radiopharmaceuticals N-13 Ammonia and Ga-68. Ionetix is now expanding its services to include the supply of alpha-emitting radioisotopes used in therapeutic radiopharmaceuticals being developed to treat various cancers. Ionetix recently established the first dedicated alpha isotope manufacturing and distribution facility to produce alpha isotopes Actinium-225 and Astatine-211 in Lansing, Michigan. Media Contact: David Eve, [email protected] SOURCE IONETIX

Radiation TherapyLicense out/in

15 May 2023

·www.globenewswire.com

POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer

POINT further strengthens supply chain with $10 million investment in Ionetix Alpha Corp.INDIANAPOLIS and LANSING, Mich., May 15, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, and IONETIX Corporation (“IONETIX”), a leading cyclotron technology and isotope manufacturing company, announced a collaboration to create Ionetix Alpha Corp. (Ionetix-). Ionetix-, a new subsidiary of IONETIX, is focused on near-term, commercial-scale production of Good Manufacturing Practice (GMP) grade therapeutic isotopes, such as actinium-225 (225Ac). “Access to GMP grade therapeutic isotopes like 225Ac continues to be a key rate-limiting factor in the clinical development of next generation radioligands,” said Dr. Joe McCann, Chief Executive Officer of POINT. “With this investment, POINT is demonstrating its ongoing commitment to overcoming the barriers that have historically limited radioligand development, positioning us uniquely in this emerging high potential therapeutic modality.” “Having already produced our first alpha-emitting radionuclide earlier this year in Lansing, we are excited to work with POINT to scale production of 225Ac,” said Kevin Cameron, Chairman of IONETIX. “Our investment in commercial-scale production of 225Ac has the potential to benefit patients around the globe by enabling life-changing access to these new therapeutic radiopharmaceuticals.” IONETIX has transferred its alpha therapy isotope business assets into Ionetix-. POINT will invest $10 million into Ionetix-. Ionetix- will initially produce and distribute 225Ac from its isotope production and manufacturing facility located in Lansing, Michigan. This first-of-its kind facility is highly specialized and dedicated exclusively to the production and distribution of alpha-emitting radionuclides using cyclotrons. The first of two cyclotrons have been installed and commissioned. About POINT Biopharma Global Inc.POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT aims to transform precision medicine by combining a portfolio of targeted radioligand assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for medical isotopes including actinium-225 and lutetium-177. POINT’s active clinical trials include FRONTIER, the phase 1 trial for PNT2004, a pan-cancer program targeting fibroblast activation protein-α (FAP-α), and SPLASH, the phase 3 trial for 177Lu-PNT2002 for people with metastatic castration resistant prostate cancer (mCRPC) after second-line hormonal treatment. Learn more about POINT Biopharma Global Inc. at https://www.pointbiopharma.com/. About IONETIX CorporationIonetix Corporation is a leading cyclotron technology innovator. Utilizing a proprietary cyclotron technology platform, Ionetix is focused on developing innovative solutions for the production and distribution of radioisotopes used for diagnostic and therapeutic radiopharmaceuticals. Ionetix offers turnkey services for the point-of-care supply of diagnostic positron emission tomography (PET) radiopharmaceuticals N-13 Ammonia and Ga-68. Ionetix is now expanding its services to include the supply of therapeutic alpha isotopes used in radiopharmaceuticals being developed to treat various cancers. Ionetix recently established the first dedicated alpha isotope manufacturing and distribution facility to produce alpha isotopes Actinium-225 and Astatine-211 in Lansing, Michigan. https://www.ionetix.com/ Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the benefits of the recently completed business combination, as well as statements about the potential attributes and benefits of POINT’s product candidates and the format and timing of POINT’s product development activities and clinical trials. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, our ability to grow and manage our growth profitably and retain our key employees, the impact of COVID-19 on our business, the success, cost and timing of our product development activities and clinical trials, our ability to obtain and maintain regulatory approval for our product candidates, our ability to obtain funding for our operations, our the ability to maintain the listing of our common stock on the NASDAQ, changes in applicable laws or regulations, the possibility that POINT may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described in our Annual Report on Form 10-K filed with the SEC on March 27, 2023. Many of these factors are outside of POINT’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. POINT Biopharma Contact:Daniel PearlsteinDirector, Strategyinvestors@pointbiopharma.com IONETIX Contact:David Evedeve@ionetix.com812-972-0673

Phase 3

15 May 2023

·www.biospace.com

POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope ManufacturerPOINT further strengthens supply chain with $10 million investment in Ionetix Alpha Corp.

INDIANAPOLIS and LANSING, Mich., May 15, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, and IONETIX Corporation (“IONETIX”), a leading cyclotron technology and isotope manufacturing company, announced a collaboration to create Ionetix Alpha Corp. (Ionetix-). Ionetix-, a new subsidiary of IONETIX, is focused on near-term, commercial-scale production of Good Manufacturing Practice (GMP) grade therapeutic isotopes, such as actinium-225 (225Ac). “Access to GMP grade therapeutic isotopes like 225Ac continues to be a key rate-limiting factor in the clinical development of next generation radioligands,” said Dr. Joe McCann, Chief Executive Officer of POINT. “With this investment, POINT is demonstrating its ongoing commitment to overcoming the barriers that have historically limited radioligand development, positioning us uniquely in this emerging high potential therapeutic modality.” “Having already produced our first alpha-emitting radionuclide earlier this year in Lansing, we are excited to work with POINT to scale production of 225Ac,” said Kevin Cameron, Chairman of IONETIX. “Our investment in commercial-scale production of 225Ac has the potential to benefit patients around the globe by enabling life-changing access to these new therapeutic radiopharmaceuticals.” IONETIX has transferred its alpha therapy isotope business assets into Ionetix-. POINT will invest $10 million into Ionetix-. Ionetix- will initially produce and distribute 225Ac from its isotope production and manufacturing facility located in Lansing, Michigan. This first-of-its kind facility is highly specialized and dedicated exclusively to the production and distribution of alpha-emitting radionuclides using cyclotrons. The first of two cyclotrons have been installed and commissioned. About POINT Biopharma Global Inc. POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT aims to transform precision medicine by combining a portfolio of targeted radioligand assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for medical isotopes including actinium-225 and lutetium-177. POINT’s active clinical trials include FRONTIER, the phase 1 trial for PNT2004, a pan-cancer program targeting fibroblast activation protein-α (FAP-α), and SPLASH, the phase 3 trial for 177Lu-PNT2002 for people with metastatic castration resistant prostate cancer (mCRPC) after second-line hormonal treatment. Learn more about POINT Biopharma Global Inc. at . About IONETIX Corporation Ionetix Corporation is a leading cyclotron technology innovator. Utilizing a proprietary cyclotron technology platform, Ionetix is focused on developing innovative solutions for the production and distribution of radioisotopes used for diagnostic and therapeutic radiopharmaceuticals. Ionetix offers turnkey services for the point-of-care supply of diagnostic positron emission tomography (PET) radiopharmaceuticals N-13 Ammonia and Ga-68. Ionetix is now expanding its services to include the supply of therapeutic alpha isotopes used in radiopharmaceuticals being developed to treat various cancers. Ionetix recently established the first dedicated alpha isotope manufacturing and distribution facility to produce alpha isotopes Actinium-225 and Astatine-211 in Lansing, Michigan. Forward Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the benefits of the recently completed business combination, as well as statements about the potential attributes and benefits of POINT’s product candidates and the format and timing of POINT’s product development activities and clinical trials. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, our ability to grow and manage our growth profitably and retain our key employees, the impact of COVID-19 on our business, the success, cost and timing of our product development activities and clinical trials, our ability to obtain and maintain regulatory approval for our product candidates, our ability to obtain funding for our operations, our the ability to maintain the listing of our common stock on the NASDAQ, changes in applicable laws or regulations, the possibility that POINT may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those described in our Annual Report on Form 10-K filed with the SEC on March 27, 2023. Many of these factors are outside of POINT’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. POINT Biopharma Contact: Daniel Pearlstein Director, Strategy investors@pointbiopharma.com IONETIX Contact: David Eve deve@ionetix.com 812-972-0673

Phase 3Radiation Therapy

100 Deals associated with AMMONIA N-13

External Link

KEGG	Wiki	ATC	Drug Bank
-	AMMONIA N-13	V09	DB09326

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Coronary Artery Disease	US	The Feinstein Institutes for Medical Research	23 Aug 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EANM2024	Not Applicable	-	108	Patients who received beta-blockers	nhzkjsujoq(qckjfjvcqf) = hvssikcomp fyfjkadeoh (ioxsolznvy, 0.54 - 0.78) View more	Positive	27 Sep 2024
				13N-ammonia (Patients who did not receive beta-blockers)	nhzkjsujoq(qckjfjvcqf) = pyamiqlqwb fyfjkadeoh (ioxsolznvy, 0.55 - 0.76) View more
ClinicalTrials.gov (SNMMI2024)	Not Applicable	Angina, Stable	21	13N-Ammonia PET Myocardial Perfusion Imaging	nrvclcvxjn(mhumitdkhb) = mwqevtjfun ylgioznnas (wcitixqcss ) View more	Positive	09 Jun 2024
EANM2022	Not Applicable	13 N-ammonia	9	13 N-ammonia (Automatic injection unit (microDDS))	hqsbgrgncs(aabvapezzm) = avjvqmwgqp muslhmrrya (xkquslqjoq, 4.21)	Positive	22 Sep 2022
				13 N-ammonia (Manual injection with shielded syringe)	hqsbgrgncs(aabvapezzm) = uagavqaywz muslhmrrya (xkquslqjoq, 6.85)
SNMMI2021	Not Applicable	Cardiovascular Diseases	-	N13 ammonia PET/CT	dpsmvgjysz(gedsypzehm) = nimievxrpe clxhjeiite (gmgskztosm )	-	18 May 2021
SNMMI2020	Not Applicable	Coronary microvascular dysfunction \| Overweight \| Obesity	-	13 N-ammonia (Normal weight (BMI 18.5-23.9))	dcphumrddn(fqiggwcqnp) = nkbrfkxssb mnvwhbyzzw (jlrjsltijm, 9.57) View more	-	15 May 2020
				13 N-ammonia (Overweight (BMI 24.0-27.9))	dcphumrddn(fqiggwcqnp) = qqbpmqxpmm mnvwhbyzzw (jlrjsltijm, 9.89) View more
ESC2019	Not Applicable	Heart failure with normal ejection fraction	24	13N-ammonia	qkojyqviod(oeaqlshnqd) = uyhjkprtql tiyxpwjpub (hfmqmpvuuu )	-	06 Dec 2019
EANM2019	Not Applicable	Coronary Artery Disease	80	[13N] -Ammonia (Patients with intermediate stenoses of one and more coronary arteries (50%-70%))	rifflgnrot(mntlliscln) = grdnhxsgss ysnlavcqzz (deybeuyoaq ) View more	-	18 Sep 2019
SNMMI2019	Not Applicable	Sleep Apnea, Obstructive	-	13 N-Ammonia (Mild OSA)	czqnzlcyns(gzefqqvhbu) = fafygfifce izddrucknw (xagupzegoj, 1.01) View more	-	21 May 2019
				13 N-Ammonia (Moderate OSA)	czqnzlcyns(gzefqqvhbu) = bccdkotmnk izddrucknw (xagupzegoj, 0.88) View more
EANM2018	Not Applicable	-	22	13 N-ammonia (Transluminal Attenuation Gradient (TAG))	kumhuzjzvu(tnkylofeta) = gujusnlytt hroexbuqcc (zcypaeoxnl, -11.1)	Positive	18 Sep 2018
Zurich Quantitative PET Registry (ESC2018)	Not Applicable	Ischemic cardiomyopathy left ventricular ejection fraction \| coronary artery disease	110	13N-ammonia	sxjtkfivfg(fzyonbtsua) = trended towards higher values in scarred myocardium gjcedobgxj (jteqmlqilm )	-	25 Aug 2018
				13N-ammonia

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis